Evolent Health, Inc. (NYSE:EVH) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets boosted its position in shares of Evolent Health, Inc. (NYSE:EVH) by 150.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,469 shares of the technology company’s stock after buying an additional 15,299 shares during the quarter. BNP Paribas Financial Markets’ holdings in Evolent Health were worth $720,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of EVH. William Blair Investment Management LLC raised its position in shares of Evolent Health by 35.2% during the 2nd quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after purchasing an additional 1,308,376 shares during the last quarter. First Light Asset Management LLC raised its holdings in shares of Evolent Health by 401.5% during the second quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company’s stock valued at $27,634,000 after acquiring an additional 1,157,124 shares during the last quarter. Engaged Capital LLC lifted its position in shares of Evolent Health by 26.1% in the second quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock valued at $78,611,000 after acquiring an additional 850,000 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Evolent Health by 24.8% in the second quarter. Bank of New York Mellon Corp now owns 2,048,341 shares of the technology company’s stock worth $39,164,000 after acquiring an additional 406,837 shares during the last quarter. Finally, Foundry Partners LLC purchased a new stake in shares of Evolent Health during the third quarter worth approximately $10,042,000.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on EVH. Citigroup lowered their target price on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Stephens lowered shares of Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $38.00 to $16.00 in a report on Friday, November 8th. KeyCorp started coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price for the company. JPMorgan Chase & Co. reduced their price target on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, November 22nd. Finally, Oppenheimer cut their price objective on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $26.18.

Evolent Health Price Performance

EVH stock opened at $11.40 on Friday. The firm has a market cap of $1.33 billion, a P/E ratio of -12.53 and a beta of 1.45. The stock has a 50-day simple moving average of $18.48 and a 200-day simple moving average of $22.61. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. Evolent Health, Inc. has a 1 year low of $10.82 and a 1 year high of $35.00.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.